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Fludarabine, Carmustine, and Thiotepa for Acute
Lymphoblastic Leukemia and Other Hematologic
Malignancies Necessitating Enhanced Central Nervous
System Activity
Petros Christopoulos,1 Hartmut Bertz,1 Gabriele Ihorst,2 Reinhard Marks,1 Ralph W€asch,1
J€urgen Finke1Total body irradiation has been the mainstay of conditioning since the inception of allogeneic hematopoietic
cell transplantation, but toxicity often precludes its use. For less-fit patients with acute lymphoblastic leuke-
mia and other hematologic malignancies frequently affecting the central nervous system, we designed a radi-
ation-free regimen with fludarabine (25 mg/m2/day on days26 to24), carmustine (400 mg/m2 on day26),
and thiotepa (5 mg/kg twice daily on days25 and24), all of which readily penetrate the blood-brain barrier
and have potent antileukemic and lymphotoxic activity. Here we present a series of 30 consecutive patients
with high-risk or relapsed disease who underwent allogeneic hematopoietic cell transplantation with this
protocol. The median patient age was 60 years (range, 42-70 years), and the median follow-up was 968
days (range, 58-1989 days). Graft-versus-host disease prophylaxis consisted of cyclosporine A and alemtu-
zumab (10-20 mg). At 2 years, overall survival was 52% (95% confidence interval [CI], 34%-71%), event-
free survival was 39% (95% CI, 22%-57%), cumulative incidence of relapse/progression was 30% (95% CI,
17%-52%), and treatment-related mortality was 31% (95% CI, 18%-53%). Neurologic toxicity is a concern,
especially in older and heavily pretreated patients. Our experience indicates the feasibility of this regimen
as an alternative to total body irradiation and a potentially curative option for less-fit patients who need
a highly central nervous system–active conditioning.
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The use of intensive therapy regimens followed
by allogeneic hematopoietic cell transplantation
(allo-HCT) is an established curative treatment for
high-risk hematologic malignancies. Total body irra-
diation (TBI) has been the mainstay of such regimens
ever since the inception of allo-HCT [1]. However,1Department of Hematology/Oncology; and 2Clinical
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6/j.bbmt.2012.02.016TBI-related toxicity increases with patient age [2],
and its use is associated with increased risk of
acute graft-versus-host disease (aGVHD) [3,4] and
secondary malignancies in adult patients [5]. Although
TBI is clearly effective in treating pediatric patients
with acute lymphoblastic leukemia (ALL) [6,7], its
effectiveness in other hematologic malignancies does
not clearly outweigh its known side effects [8].
Involvement of the central nervous system (CNS)
in ALL and other hematologic malignancies poses
a special therapeutic problem, given that most drugs
do not readily penetrate the blood-brain barrier [9].
CNS involvement is noted in 5% of patients
with ALL at primary diagnosis, but in up to 20%-
30% of patients at relapse [10,11]. Less frequently, it
can complicate the course of acute myelogenous
leukemia (AML) [12] and non-Hodgkin lymphoma
(NHL), especially the aggressive subtypes [13,14].
Buildingon thegoodexperiencewith ourhigh-dose
chemotherapy regimen for primary CNS lymphomas
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active allogeneic conditioning regimen also suitable
for patients not fit enough for TBI. As for PCNSL,
we used high doses of the lipophilic alkylating agents
carmustine (BCNU) and thiotepa, which achieve cere-
brospinal fluid (CSF) levels in the range of 50%-80%
of plasma levels for BCNUand up to 100% for thiotepa
[15]. The doses chosen are well below the reported
thresholds for severe lung or liver toxicity, yet they re-
sult in severe myelotoxicity requiring HCT [16,17].
Thiotepa in particular is tolerated with little organ
toxicity and offers potent antileukemic and stem cell
toxic activity [18-20]. To these 2 drugs we added
fludarabine, which also readily crosses the blood-brain
barrier. Fludarabine was chosen for its potent lympho-
cytotoxicity, which facilitates engraftment [21], and for
the fact that it inhibits DNA repair, thereby enhancing
the cytotoxic activity of alkylating agents [22]. GVHD
prophylaxis consisted of cyclosporine A and alemtuzu-
mab, as described previously [23].
Here we report the results of 30 consecutive pa-
tients with ALL and other hematologic malignancies
treated with this novel regimen.PATIENTS AND METHODS
Patients
Thirty patients underwent allo-HCT between
November 2005 and April 2010, with prospective
data collection and simultaneous analysis in April
2011. Included were consecutive cases of ALL in pa-
tients not suitable for TBI-based conditioning and
cases of other hematologic malignancies with CNS in-
volvement or at high risk for CNS redundant word in-
volvement. TBI was not performed due to either
advanced age (.55 years) or comorbidities, including
probable (n 5 1) or possible (n 5 2) invasive aspergil-
losis in 3 of 8 patients aged#55 years. All patients pro-
vided written informed consent for treatment and data
evaluation according to the Declaration of Helsinki.
Patient characteristics are summarized in Table 1.
Diagnoses and disease status at the time of allo-HCT
were ALL in 22 patients, with 17 in complete remis-
sion (CR) and 5 in relapse, including 1 chemoresistant
case (defined as \50% tumor reduction with pre-
transplantation chemotherapy); AML with meningeal
involvement in 2 patients; chronic myelogenous leuke-
mia in lymphatic blast crisis with meningeal involve-
ment in 1 patient; and NHL/chronic lymphocytic
leukemia (CLL) in 5 patients, 2 of whom had overt
CNS disease, 1 with CLL 11q222 with progressive
disease (PD) and meningeal involvement (proven
with flow cytometry) after alemtuzumab, and 1 with
a Richter transformation of CLL and meningeal in-
volvement in partial remission after R-CHOP and in-
trathecal chemotherapy. Three other patients receivedthis protocol because they had high-risk NHLwith re-
lapsed and/or refractory and/or extranodal disease,
which increase the risk for CNS involvement: 1 patient
with diffuse large B-cell lymphoma transformation of
a relapsed follicular lymphomawith lung and bowel in-
volvement in PD after R-CHOP; 1 patient with sec-
ondary T-NHL (diagnosed 10 years after treatment
of a marginal-zone lymphoma) relapsed after initial
treatment, with multifocal bowel involvement, who
achieved a second CR with salvage therapy before
allo-HCT; and 1 patient with angioimmunoblastic
T-NHL with PD after first- and second-line chemo-
therapy. All patients had received at least 1 cycle of
chemotherapy before transplantation, but none had
been autografted or allografted.
Sixteen of the 22 patients with ALL had high-risk
disease based on bcr-abl expression (n 5 10), initial
leukocyte count .30  109/L in B-ALL (n 5 7), ab-
sent CD1a expression in a pre–T-ALL (n5 1), or pri-
mary induction failure (n 5 4). All of these patients
underwent transplantation in first CR (CR1), except
for 1 patient whose treatment had to be interrupted be-
cause of progressive invasive aspergillosis. Imatinib at
an initial dose of 600 mg/day was included in the in-
duction of bcr-abl1ALL and stopped 1-2 weeks before
conditioning. Tyrosine kinase inhibitors were not
given routinely posttransplantation, but imatinib was
offered initially at 400mg/day to the bcr-abl1ALL pa-
tient who relapsed after allo-HCT, and was changed
after disease progression to nilotinib 800 mg/day and
dasatinib 140 mg/day along with other treatments, in-
cluding donor lymphocyte infusion and chemotherapy
until a second allo-HCT was performed. Standard-
risk patients were consolidated with chemotherapy
and underwent transplantation after their first relapse.
None of the patients with ALL had CNS involvement
at the time of allo-HCT.Donor, Graft, and Transplantation
Characteristics
HLA class I antigens were typed by serology or
intermediate-resolution DNA techniques (2 digits;
n 5 25) until April 2009 and with high-resolution
DNA techniques thereafter (4 digits; n5 5). HLA class
II antigens were typed by high-resolution DNA tech-
niques.
Donors were HLA-identical siblings (n 5 6) and
HLA-matched (HLA-A, -B, -DRB1, and -DQB1) vol-
unteers (n5 24; 18 HLA-identical, 5 with 1 mismatch,
1 with 2 mismatches).
The median age of the donors was 42 years (range,
20-68 years). All recipients received granulocyte
colony-stimulating factor–mobilized unmanipulated
peripheral blood stem cells, except for 1 recipient
who received bone marrow. Eighteen recipients
received a graft from a same-sex donor, while 12
Table 1. Patient Characteristics
Number of patients 30
Age, years, median (range) 60 (42-70)
Karnofsky score at transplantation, median (range) 85 (50-100)
Sex, n (%)
Male 18 (60)
Female 12 (40)
Disease and remission status at allo-HCT, n (%)
ALL SR HR* bcr-abl+ 22 (73)
CR1 6 9 15
CR2 2 2
REL1 chemosensitive 3 3
REL1 chemoresistant† 1 1
REL2 chemosensitive 1 1
AML 2 (7)
CR2 1
PIF 1
BC CML (lymphatic) 1 (3)
NHL/CLL‡ B-NHL T-NHL 5 (17)
CR 1 1
PR 1 1
PD 2 1 3
Days from diagnosis to allo-HCT, median (range) 226 (98-4813)
Donors, n (%)
HLA-identical sibling 6 (20)
Unrelated, HLA-identical§ 18 (60)
Unrelated, HLA-mismatched 6 (20)
Donor–recipient sex match, n (%)
Matched 18 (60)
Mismatched 12 (40)
Male recipient and female donor 7 (23)
CMV serology: patient–donor pairs at risk for
reactivation, n (%)
24 (80)
GVHD prophylaxis with cyclosporine A
/alemtuzumab, n (%)
30 (100)
BC CML indicates chronic myelogenous leukemia in blast crisis; bcr-abl+,
bcr-abl–positive ALL; CML, chronic myelogenous leukemia; HR, high-
risk; PIF, primary induction failure; PR, partial remission; REL, relapse;
SR, standard risk.
*Criteria for high-risk ALL: bcr-abl expression (listed separately on the
right), high initial leukocyte count (>30  109/L) in B-ALL, primary in-
duction failure, absent CD1a expression in pre–T-ALL.
†Chemoresistant disease: tumor reduction of <50% with pretransplan-
tation chemotherapy.
‡Details of the diagnoses are provided in the text.
§HLA-matched for HLA-A, -B, -DR, and -DQ.
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7 male recipient–female donor pairs. Twenty-four
patients were at risk for cytomegalovirus (CMV) reac-
tivation (CMV-positive donor or recipient).
Conditioning Regimen, GVHD Prophylaxis, and
Supportive Care
The FBTT conditioning regimen consists of flu-
darabine 25 mg/m2/day on days26,25, and24 (total
dose, 75 mg/m2) as a 1-hour infusion; BCNU 400
mg/m2 on day 26 as a 2-hour infusion; and thiotepa
5 mg/kg/day twice daily on days 25 and 24 (total
dose, 20 mg/kg) as a 2-hour infusion beginning 2 hours
after the end of fludarabine (n 5 18 patients). As fore-
seen by the protocol, the BCNU dose was reduced to
300 mg/m2 (n5 12) because of previous mediastinal ir-
radiationorpreexisting lungdisease, such as sarcoidosis,
asthma, tuberculosis, recent pneumonia, or smoking
history and mild obstructive or restrictive changes inpulmonary function tests in 8 of 22 ALL patients and
in 4 of 8 patients with other diagnoses. Two patients re-
ceived fludarabine 30 mg/m2/day as ordered by the at-
tending physician. The unmanipulated grafts were
infused on day 0.
In all patients, GVHD prophylaxis consisted of i.v.
cyclosporine A starting on day23 at a dose of 2.5 mg/
kg i.v. twice a day (trough level, 250-350 ng/mL), in
combination with low-dose alemtuzumab (MabCam-
path; Schering, Berlin, Germany) given i.v. over 2
hours, as described previously [23]. Initially, alemtuzu-
mab was given at a total dose of 20 mg by infusing 10
mg/day on days 22 and 21 (n 5 4). Starting in June
2006, patients received a single dose of 10 mg on
day 21 (n 520), except in patients with HLA-
mismatched grafts (n5 5) or CLL (n5 1). In patients
without GVHD, cyclosporine was usually tapered
starting on day 160 and discontinued at around
day 1120. Standard supportive care was provided as
described previously, including preemptive therapy
with ganciclovir, valganciclovir, or foscarnet for 1 pos-
itive polymerase chain reaction (PCR) assay for CMV
with a copy number .3000/mL or 2 consecutive pos-
itive CMV PCR assays of .1000/mL [23].
Severity Scoring of Adverse Events and GVHD
Adverse events were scored using the National
Cancer Institute’s Common Terminology Criteria
for Adverse Events version 4.0 [24], with grade 5 de-
noting fatalities and grade 4 corresponding to life-
threatening events requiring urgent intervention,
such as trepanation or plasmapheresis (for neurologic
events), intubation (for pulmonary or neurologic
events), hemodialysis (for renal events), high-dose opi-
oids with total parenteral nutrition (for mucositis), and
transfer to the intensive care unit (for infections).
Acute GVHD (aGVHD) was graded according to
the International Bone Marrow Transplant Registry
criteria [25]. Chronic GVHD (cGVHD) was charac-
terized as limited or extensive according to the defini-
tions of Schulman et al. [26].
Statistical Analysis
Overall survival (OS) and event-free survival (EFS)
were estimated and plotted with the method of
Kaplan-Meier using SAS version 9.2 (SAS Institute
GmbH, Frankfurt, Germany). OS was calculated
from the date of transplantation to the date of death
from any cause. EFS was calculated from the date of
transplantation to the date of death from any cause
or progression, whichever occurred first. If the event
of interest was not observed, then observations were
censored at the latest date of documented survival or
survival without progression.
Cumulative incidents of treatment-related mortal-
ity (TRM), relapse/progression, and GVHDwere also
Table 2. Adverse Events
Nonhematologic adverse events (grade) 3 4 5
Infections (pneumonias) (n 5 27)* 17 (15) 4 (4) 6 (4)†
Neurologic (n 5 8) 3 3 2
Pulmonary (n 5 3) 3 0 0
Cardiac (n 5 0) 0 0 0
Renal (n 5 6) 1 5 0
Mucositis (n 5 8) 4 4 0
aGVHD (grade) II III IV
Patients (of 30 evaluable; n 5 7), n 2 2 3
cGVHD Limited Extensive
Patients (of 25 evaluable; n 5 11), n 3 8
In parentheses are the numbers of pneumonias.
*Excluding febrile neutropenia. Numbers indicate events.
†Four of the 6 fatal infections occurred in the context of immunosup-
pression due to cGVHD.
Table 3. Causes of Death
Cause of Death All Patients ALL subgroup
Progression/relapse, n 6 3
Infection, n 6* 5
Intracranial hemorrhage, n 2 2
aGVHD, n 1 1
Secondary malignancy, n 1† –
*Four of the 6 fatal infections occurred in the context of immunosup-
pression due to cGVHD.
†A bronchial carcinoma of the right lung in an ex-smoker (25 pack-years)
who was heavily pretreated with anthracyclines, etoposide, and irradia-
tion of the right axilla and supraclavicular region for his lymphoma be-
fore transplantation.
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from the date of transplantation until death without ev-
idence of relapse/progression, with relapse/progres-
sion as a competing risk. The risks of relapse/
progression and GVHD were calculated from the
date of transplantation until the date of documented re-
lapse/progression or GVHD, with competing risks of
death without relapse/progression or death without
GVHD, respectively. Age was compared in patient
groups using the Mann-Whitney U test.RESULTS
Engraftment, Chimerism, and TransfusionNeeds
All patients engrafted with neutrophils $0.5 
109/L on median day 116 (range, day 110 to day
126), and 28 of 30 patients engrafted with $20 
109/L platelets on day 110 (range, day 17 to day
148). Two patients remained dependent on platelet
transfusions despite full donor chimerism until death,
1 on day 158 and 1 on day 1155. None received
granulocyte colony-stimulating factor. After 1 month,
26 of 30 patients exhibited full donor chimerism (de-
fined as .99% donor, assessed by capillary electro-
phoresis of amplified microsatellite DNA in bone
marrow in 25 patients and in blood in 1 patient), and
the remaining 4 patients had mixed chimerism. No
primary or secondary graft failure occurred. Until sta-
ble engraftment, a median of 6 (range, 0-73) units of
packed red blood cells and 4 (range, 1-92) units of
apheresis platelets per patient were transfused.
Nonhematologic Adverse Events
Over the entire follow-up period, a total of 24
severe (grade 4-5) nonhematologic adverse events
occurred in 14 patients, with a fatal outcome in 8 cases
due to pneumonia (n 5 4), sepsis with unknown focus
(n 5 1), human herpesvirus 6 (HHV-6) encephalitis
(n 5 1), and intracranial hemorrhage (n 5 2)
(Tables 2 and 3).
The 2 fatal neurologic-related cases deserve special
mention. Both were patients with ALL without CNSinvolvement who were treated prophylactically in
accordance with the German ALL study protocol,
with cranial irradiation and intrathecal chemotherapy
before transplantation. One patient developed bilat-
eral subdural hematomas and intermittent nonconvul-
sive epileptic activity during the fifth week after
allo-HCT, remained in a stupor thereafter, and died
with pneumonia on day 189. A CNS infection was
ruled out by appropriate CSF tests, including PCR
for herpes simplex virus, varicella-zoster virus, CMV,
Epstein-Barr virus, HHV-6, and JC virus. The second
patient exhibited cognitive decline during an episode
of severe sepsis in the second week posttransplanta-
tion. Despite resolution of the infection, he showed
further discrete behavioral impairment in the ensuing
months and died of intracranial hemorrhage on day
1136. CSF studies were unrevealing, and serial brain
imaging showed progressive leukoencephalopathy.
Eight of the 30 patients experienced a grade 3-5
neurologic adverse event, with grade 3 denoting stupor
or encephalopathy limiting self-care (Table 2). Com-
pared with the total series, these patients were older
at the time of transplantation (median, 63 years versus
59 years; P 5 .05), but did not differ significantly in
terms of CNS involvement (1 of 8 versus 4 of 22) or
previous CNS irradiation (3 of 8 versus 8 of 22) or in-
trathecal chemotherapy at any time (7 of 8 versus 19 of
22) or during the week preceding conditioning (3 of 8
versus 4 of 22).Infectious Complications
Six of the 30 patients had received antifungal ther-
apy for probable (n 5 2) or possible (n 5 4) invasive
aspergillosis before transplantation [27]. During neu-
tropenia, all patients experienced fever and required
i.v. antibiotics. During the entire follow-up period, 8
of 30 patients experienced sepsis that required inten-
sive care (either intubation or hemodialysis), and 16
of 30 experienced pneumonia, 4 with a fatal outcome
(Tables 2 and 3). CMV reactivation/infection requir-
ing preemptive therapy occured in 15 of 24 patients
considered at-risk, and CMV pneumonia occurred in
3 of these 24 patients, including 1 fatal case. One
Table 4. Outcome Parameters at 2 Years
All Patients ALL Subgroup
OS 52.3 (34.0-70.6)* 59.1 (38.5-79.6)
EFS 39.4 (21.7-57.1) 45.5 (24.6-66.3)
RI/PI 30.0 (17.4-51.8) 22.7 (10.5-49.1)
TRM 30.6 (17.7-52.9) 31.8 (17.3-58.7)
cGVHD 38.2 (23.8-61.2) 37.9 (21.8-65.9)
cGVHD extensive 28.0 (15.5-50.8) 33.1 (17.9-61.1)
aGVHD II-IV† 23.3 (12.2-44.6) 18.2 (7.5-44.1)
aGVHD III-IV† 16.7 (7.5-37.1) 9.1 (2.4-34.1)
RI/PI indicates incidence of relapse/progression.
*Percent probability (95% CI). OS and EFS were estimated according to
the method of Kaplan-Meier. RI/PI, TRM, and GVHD were calculated as
cumulative incidents with consideration of competing risks.
†Cumulative risks for aGVHD refer to day +100 after allo-HCT.
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organic psychosyndrome in the fourth week after
allo-HCT and died with pneumonia on day 171. In
this patient, very high HHV-6 copy numbers were de-
tected in both CSF (436,400 copies/mL) and blood
(39,080 copies/mL) at the onset of neurologic symp-
toms, compared with negative results in samples ana-
lyzed earlier.
GVHD
Grade II aGVHDwas observed in 2 of 30 patients,
and grade III-IV aGVHD occurred in 5 of 30 patients
(Table 2), the latter with skin (n5 4), gut (n5 4), and/
or liver (n5 2) involvement. One patient died of grade
IV aGVHDof the gut on day158, and another patient
had grade IV aGVHD of the gut when he died of PD
on day 1155.
Twenty-five patients were evaluable for cGVHD.
Of these 25 patients, 14 had no cGVHDand 3 had lim-
ited cGVHD (Table 2); 7 of these 17 patients relapsed.
In contrast, all 8 patients with extensive cGVHD re-
mained relapse-free. At 2 years posttransplantation,
the incidence of cGVHD was 38% (95% confidence
interval [CI], 24%-61%), and the incidence of exten-
sive cGVHDwas 28% (95%CI, 16%-51%) (Table 4).
Response, Survival, Relapse/Progression, and
Causes of Death
The best remission status after allo-HCT was CR
in 26 of 30 patients, stable disease in 2 patients, and PD
in 1 patient. One patient with ALL was not evaluable
for response because of early death due to aGVHD.
At the time of this report, 14 patients were alive,
with a median follow-up of 947 days (range, 354-
1989 days), 12 of whom were in CR. Eleven of these
12 patients had been in continuous CR since trans-
plantation, 10 of whom no longer required immuno-
suppression. The median follow-up of all 30 patients
was 968 days (range, 58-1989 days). Two-year OS
was 52% (95% CI, 34%-71%), and 2-year EFS was
39% (95% CI, 22%-57%) (Table 4 and Figure 1A).
Six patients relapsed from CR, and all 3 patientswithout CR demonstrated PD posttransplantation.
The incidence of relapse/progression at 2 years post-
transplantation was 30% (95% CI, 17%-52%)
(Table 4 and Figure 1B).
Sixteen of the 30 patients have died, including 3
deaths in the first 100 days posttransplantation, due
to either relapse/progression of the malignancy (n 5
6) or nonrelapse causes (n 5 10). Reasons for TRM
were infection (n 5 6), aGVHD grade IV (n 5 1),
intracranial hemorrhage (n 5 2), and secondary
malignancy (n 5 1) (Table 3). TRM at 2 years post-
transplantation was 31% (95% CI, 18%-53%)
(Table 4 and Figure 1B).
ALL Patients
All 21 evaluable ALL patients were in CR after
allo-HCT. At the time of this report, 11 patients
were alive, 9 in continuous CR, with a median
follow-up of 968 days (range, 354-1989 days). One pa-
tient was in second CR with extensive cGVHD at 385
days after a second allo-HCT, and 1 patient was in re-
lapse and receiving therapy with blinatumomab.
Causes of death were relapse (n 5 3), infections
(n5 5), intracranial hemorrhage (n5 2), and aGVHD
(n5 1). At 2 years, OS was 59% (95% CI, 39%-80%),
EFS was 46% (95% CI, 25%-66%), the rate of re-
lapse/progression was 23% (95% CI, 11%-49%),
and the TRM was 32% (95% CI, 17%-59%)
(Table 4 and Figure 2).DISCUSSION
We present a series of 30 consecutive patients with
ALL and other hematologic malignancies who under-
went allo-HCT with a novel FBTT conditioning reg-
imen comprising fludarabine, BCNU, and thiotepa.
When developing this protocol, we first pursued
a highly CNS-active chemotherapy by choosing drugs
that readily penetrate the blood–brain barrier and have
potent antileukemic and lymphotoxic activity [15,22].
This allowed us to omit TBI and made allo-HCT fea-
sible for patients considered less fit due to advanced
age, comorbidities, or overt CNS involvement. A fa-
vorable toxicity profile was facilitated by the better tol-
erability of fludarabine and thiotepa compared with
traditional alkylating agents [20,22].
Our FBTT regimen does not meet the criteria for
a ‘‘reduced-intensity’’ regimen [28]. This explains the
high rate (26 of 30) of complete donor chimerism at
1 month and the lack of graft failure. Nevertheless,
the regimen was generally well tolerated. Despite our
patients’ high median age of 60 years and extensive co-
morbidities (including probable or possible invasive
aspergillosis in 6 of the 30 patients), our TRM of
31% is comparable with previously reported TRM
rates of 30%-60% after allo-HCT in younger ALL
Figure 1. (A) Kaplan-Meier survival curve of OS and EFS for all 30 pa-
tients. At 1 year, OS was 57% (95% CI, 39%-74%) and EFS was 43% (95%
CI, 26%-61%). The median OS was 25 months (95% CI, 6.5 months to
not reached), and the median EFS was 9.8 months (95% CI, 4.5 months
to not reached). (B) Cumulative incidence of relapse/progression and
TRM of the entire cohort. At 1 year, the cumulative incidence of re-
lapse/progression was 30% (95% CI, 17%-52%), and the estimated
TRM was 27% (95% CI, 15%-48%).
Figure 2. (A) Kaplan-Meier survival curves of OS and EFS for the ALL
patients. At 1 year, OS was 59% (95% CI, 39%-80%) and EFS was 46%
(95% CI, 25%-66%). The median OS was 29 months (95% CI, 4.47
months to not reached), and the median EFS was 10.7 months (95%
CI, 4 months to not reached). (B) Cumulative incidence of relapse/pro-
gression and TRM in the ALL patients. At 1 year, the cumulative inci-
dence of relapse/progression was 23% (95% CI, 11%-49%), and the
estimated TRM was 32% (95% CI, 17%-59%).
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free regimens, such as busulfan and cyclophosphamide
(BuCy) [29-35].We would use this regimen in patients
age .50 years and younger patients not considered
suitable for TBI. To reduce toxicity and infection
rates, we are currently considering a reduced-
intensity radiation-free amendment with BCNU 300
mg/m2 on day 27, fludarabine 30 mg/m2/day on
days26,25, and24 (total dose, 90 mg/m2), and thio-
tepa 5 mg/kg/day on days26,25, and24 (total dose,
15 mg/kg).
Severe (grade III-IV) aGVHDhad a cumulative in-
cidence of 17% at1100 days, causing 1 death. Chronic
GVHD developed in 38% of patients at 2 years, which
was extensive in the majority of cases. These rates of
GVHD are similar to those reported in a previous se-
ries using low-dose alemtuzumab as GVHD prophy-
laxis [23]. Of note, none of the 8 patients with
extensive cGVHD relapsed, but 7 of the 17 patients
without extensive cGVHD relapsed. The antileukemic
effect of cGVHD is well recognized [36,37] but did not
translate to a survival benefit for our patients, given thatmost deadly infections occurred in the context of
cGVHD-related immunosuppression.
Nonrelapse deaths were attributedmainly to infec-
tion; however, the 2 noninfectious fatal neurologic
events are of special concern. In our small cohort,
the only statistically significant difference in the
patients with neurologic adverse events was older age
(median, 63 years versus 59 years). This is in agree-
ment with experience in the treatment of PCNSL,
where the risk of neurotoxicity rises significantly after
age 60 years [38]. On the other hand, both radiation
and chemotherapy are generally known to synergisti-
cally exert CNS damage [39-42]. Therefore, we have
now abandoned prophylactic intrathecal chemo-
therapy before allo-HCT, and suggest omitting
prophylactic cranial irradiation in any ALL patient
with allo-HCT planned during CR1, especially in
older patients. Notably, the omission of prophylactic
irradiation for adult ALL has been proposed by others
as well [43], whereas the value of intrathecal chemo-
therapy for the prevention of ALL relapse after allo-
HCT has been called into question [40]. Finally, we
1436 Biol Blood Marrow Transplant 18:1430-1437, 2012P. Christopoulos et al.routinely monitor our patients for HHV-6 reactiva-
tion, which is being increasingly recognized as a major
cause of neurocognitive morbidity after allo-HCT
[44].
Early disease control was very satisfactory, with
87% of all patients and 100% of ALL patients in CR
after allo-HCT. The 46% EFS of ALL patients at 2
years is comparable with the results of other series re-
porting a leukemia-free survival of 40%-50% after
TBI-based or BuCy allografting in ALL [29-35].
The risk of relapse at 2 years was 23%, similar to the
relapse rate of 20%-30% after allo-HCT in ALL pa-
tients with regimens including TBI [29-34]. Of note,
patients alive and well at 2 years after allo-HCT have
a very high probability of cure [45].
In conclusion, although the number of patients
evaluated is small and the follow-up has been relatively
short, response and survival rates to date indicate the
feasibility of our FBTT protocol as a reasonable alter-
native to TBI or BuCy and a potentially curative op-
tion for older or less-fit patients with ALL and
selected other hematologic malignancies.ACKNOWLEDGMENTS
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